JP2011530524A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011530524A5 JP2011530524A5 JP2011522218A JP2011522218A JP2011530524A5 JP 2011530524 A5 JP2011530524 A5 JP 2011530524A5 JP 2011522218 A JP2011522218 A JP 2011522218A JP 2011522218 A JP2011522218 A JP 2011522218A JP 2011530524 A5 JP2011530524 A5 JP 2011530524A5
- Authority
- JP
- Japan
- Prior art keywords
- substance
- stabilizer
- temperature
- pharmaceutical substance
- liquid formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 43
- 239000003814 drug Substances 0.000 claims 15
- 239000003381 stabilizer Substances 0.000 claims 10
- 239000012669 liquid formulation Substances 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 239000008186 active pharmaceutical agent Substances 0.000 claims 6
- 229940088679 drug related substance Drugs 0.000 claims 6
- 239000000463 material Substances 0.000 claims 6
- 239000012907 medicinal substance Substances 0.000 claims 6
- 150000004676 glycans Chemical class 0.000 claims 5
- 229920001282 polysaccharide Polymers 0.000 claims 5
- 239000005017 polysaccharide Substances 0.000 claims 5
- 230000009477 glass transition Effects 0.000 claims 4
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims 3
- 102000014914 Carrier Proteins Human genes 0.000 claims 3
- 108010078791 Carrier Proteins Proteins 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 102000004190 Enzymes Human genes 0.000 claims 3
- 108090000790 Enzymes Proteins 0.000 claims 3
- 239000003114 blood coagulation factor Substances 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 238000001035 drying Methods 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 102000037865 fusion proteins Human genes 0.000 claims 3
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 239000003102 growth factor Substances 0.000 claims 3
- 229930014626 natural product Natural products 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 229920000642 polymer Polymers 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 150000003384 small molecules Chemical class 0.000 claims 3
- 229960005486 vaccine Drugs 0.000 claims 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 229930006000 Sucrose Natural products 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 238000004108 freeze drying Methods 0.000 claims 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 230000005496 eutectics Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229940050526 hydroxyethylstarch Drugs 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims 1
- 230000001172 regenerating effect Effects 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8642608P | 2008-08-05 | 2008-08-05 | |
| US61/086,426 | 2008-08-05 | ||
| PCT/US2009/052852 WO2010017296A1 (en) | 2008-08-05 | 2009-08-05 | Lyophilization above collapse |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011530524A JP2011530524A (ja) | 2011-12-22 |
| JP2011530524A5 true JP2011530524A5 (https=) | 2012-09-13 |
| JP5785077B2 JP5785077B2 (ja) | 2015-09-24 |
Family
ID=41401614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011522218A Active JP5785077B2 (ja) | 2008-08-05 | 2009-08-05 | 崩壊温度より高温での凍結乾燥 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9884019B2 (https=) |
| EP (2) | EP2323629B1 (https=) |
| JP (1) | JP5785077B2 (https=) |
| CA (1) | CA2729972C (https=) |
| ES (2) | ES2755029T3 (https=) |
| WO (1) | WO2010017296A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008042408A2 (en) * | 2006-10-03 | 2008-04-10 | Wyeth | Lyophilization methods and apparatuses |
| AU2007234612B2 (en) * | 2006-12-14 | 2013-06-27 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein stabilization formulations |
| US7678764B2 (en) | 2007-06-29 | 2010-03-16 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein formulations for use at elevated temperatures |
| JP5323832B2 (ja) | 2007-08-07 | 2013-10-23 | アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー | 酸性水溶液中にｇｄｆ−５を含むタンパク質製剤 |
| BRPI0911048A2 (pt) * | 2008-04-14 | 2015-12-29 | Atrm Llc | formulações líquidas tamponadas de gdf-5 |
| CA2729972C (en) | 2008-08-05 | 2018-11-20 | Wyeth Llc | Lyophilization above collapse |
| US11576863B2 (en) | 2013-03-15 | 2023-02-14 | Takeda Pharmaceutical Company Limited | Formulation of an antibody and use thereof |
| WO2014144549A1 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Factor ix polypeptide formulations |
| AU2015236340B2 (en) | 2014-03-24 | 2020-02-06 | Bioverativ Therapeutics Inc. | Lyophilized factor IX formulations |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| EP3323410A1 (en) * | 2016-11-22 | 2018-05-23 | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. | Pharmaceutical parenteral formulation containing carglumic acid |
| CN107543373B (zh) * | 2017-09-06 | 2019-04-26 | 华派生物工程集团有限公司 | 一种活疫苗的冷冻干燥方法 |
| DK4364724T3 (da) | 2018-05-10 | 2025-12-22 | Regeneron Pharma | Formuleringer med høj koncentration af VEGF-receptorfusionsprotein |
| CN109369821B (zh) * | 2018-11-28 | 2021-12-14 | 四川恒通动保生物科技有限公司 | 一种黄芪多糖的高效提取制备方法 |
| CN120241997A (zh) | 2019-02-18 | 2025-07-04 | 伊莱利利公司 | 治疗性抗体制剂 |
| BR112022015272A2 (pt) | 2020-02-04 | 2022-09-20 | Regeneron Pharma | Teor de umidade residual alvo para produto de fármaco liofilizado |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5298261A (en) * | 1992-04-20 | 1994-03-29 | Oregon Freeze Dry, Inc. | Rapidly distintegrating tablet |
| BR9507909A (pt) * | 1994-06-03 | 1997-08-12 | Procter & Gamble | Formas de dosagem de rápida dissolução |
| RU2111426C1 (ru) | 1995-11-03 | 1998-05-20 | Государственный научный центр вирусологии и биотехнологии "Вектор" | Способ лиофильной сушки биопрепарата |
| DE69928500T2 (de) | 1998-03-03 | 2006-08-03 | Eli Lilly And Co., Indianapolis | Pharmazeutische zusammensetzung enthaltend den phospholipase inhibitor natrium-[[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1 h-indol-4-yl]oxy]acetat |
| DK1820516T3 (da) * | 1999-02-22 | 2013-10-28 | Univ Connecticut | Nye albuminfrie faktor VIII-præparater |
| GB9908014D0 (en) * | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
| GB0404586D0 (en) * | 2004-03-01 | 2004-04-07 | Britannia Pharmaceuticals Ltd | Improvements in or relating to organic materials |
| EP1750760B1 (en) * | 2004-06-02 | 2017-06-28 | Universal Stabilization Technologies, Inc. | Preservation by vaporization |
| CA2576549C (en) * | 2004-08-12 | 2011-01-18 | Schering Corporation | Stable pegylated interferon formulation |
| WO2006029467A1 (en) | 2004-09-16 | 2006-03-23 | Btf Pty Ltd | Rapid freeze drying process |
| WO2006081320A2 (en) * | 2005-01-27 | 2006-08-03 | Human Genome Sciences, Inc. | Pharmaceutical formulation |
| BRPI0620316A2 (pt) * | 2005-12-21 | 2011-11-08 | Wyeth Corp | formulações de proteìnas com viscosidades reduzida e seus usos |
| JP2011526356A (ja) | 2008-06-26 | 2011-10-06 | ワイス・エルエルシー | 凍結乾燥サイクルのロバスト性（ｒｏｂｕｓｔｎｅｓｓ）方策 |
| CA2729972C (en) | 2008-08-05 | 2018-11-20 | Wyeth Llc | Lyophilization above collapse |
-
2009
- 2009-08-05 CA CA2729972A patent/CA2729972C/en active Active
- 2009-08-05 US US12/536,321 patent/US9884019B2/en active Active
- 2009-08-05 ES ES09791186T patent/ES2755029T3/es active Active
- 2009-08-05 ES ES19181153T patent/ES2968301T3/es active Active
- 2009-08-05 EP EP09791186.1A patent/EP2323629B1/en active Active
- 2009-08-05 JP JP2011522218A patent/JP5785077B2/ja active Active
- 2009-08-05 WO PCT/US2009/052852 patent/WO2010017296A1/en not_active Ceased
- 2009-08-05 EP EP19181153.8A patent/EP3572073B1/en not_active Revoked
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011530524A5 (https=) | ||
| Pardeshi et al. | Process development and quality attributes for the freeze-drying process in pharmaceuticals, biopharmaceuticals and nanomedicine delivery: a state-of-the-art review | |
| Donaldson et al. | Virus-like particle vaccines: immunology and formulation for clinical translation | |
| JP2022166110A (ja) | アデノウイルスコートタンパク質由来送達賦形剤 | |
| JP6881813B2 (ja) | 核酸ワクチン | |
| Middelberg et al. | A microbial platform for rapid and low-cost virus-like particle and capsomere vaccines | |
| CN102202688B (zh) | 稳定、干燥的轮状病毒疫苗、其组合物和制备其的方法 | |
| JP5785077B2 (ja) | 崩壊温度より高温での凍結乾燥 | |
| Thérien et al. | A versatile papaya mosaic virus (PapMV) vaccine platform based on sortase-mediated antigen coupling | |
| JP2015521628A (ja) | ウイルス様粒子の精製 | |
| CN1294520A (zh) | 聚核苷酸组合物及其制备方法与用途 | |
| CN101443038A (zh) | 尼古丁-载体疫苗制剂 | |
| AU2012320243A1 (en) | Stabilisation of polypeptides | |
| KR20240046787A (ko) | 지질 나노-에멀젼 입자에 흡착된 mRNA의 동결건조 제제 | |
| JP2018533597A (ja) | 第ｖｉｉｉ因子を含有する凍結乾燥ペレットの製造方法 | |
| CN102223788A (zh) | 保存混合物及其用途 | |
| US20160000901A1 (en) | Compositions and Methods for the Production of Virus-Like Particles | |
| Zeltins | Protein complexes and virus-like particle technology | |
| EP3127550A1 (en) | Stabilizing composition for dry formulation of virus | |
| JP5841045B2 (ja) | 医薬品送達用のウイルス様粒子ベクター、その製造方法、使用、及び医薬組成物 | |
| KR100563942B1 (ko) | 분자 물질의 모듈 운반 시스템 및 그의 제조 방법 및 용도 | |
| WO2012070968A1 (ru) | Способ молекулярного дизайна и синтеза лечебных и профилактических лекарст- венных препаратов | |
| JP2012523411A5 (https=) | ||
| Lou et al. | Recent advances in freeze-drying technologies for mRNA vaccines against infectious diseases | |
| Payton et al. | Lyophilized vaccine development |